300723SZSE
🚨 Material Event

Announcement on Wholly-Owned Subsidiary Obtaining Benzbromarone Tablets Registration Certificate

✨ AI Summary

Guangzhou Yipin Red Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yipin Red Pharmaceutical Group Co., Ltd., has received a drug registration certificate for Benzbromarone Tablets from the NMPA. This approval allows the company to market the drug in China, strengthening its product pipeline in the gout and hyperuricemia treatment field and enhancing its core competitiveness. The company anticipates potential sales risks due to market and environmental uncertainties.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300723

Securities Abbreviation: Yipin Red

Announcement No.: 2026-045

Yipin Red Pharmaceutical Group Co., Ltd.

Announcement on Wholly-Owned Subsidiary Obtaining Benzbromarone Tablets Registration Certificate

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or significant omissions.

Yipin Red Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") announces that its wholly-owned subsidiary, Guangzhou Yipin Red Pharmaceutical Co., Ltd., recently received a "Drug Registration Certificate" for Benzbromarone Tablets issued by the National Medical Products Administration. The relevant matters are hereby announced as follows:

I. Main Information of the Drug Registration Certificate

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.